Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Cash Flows

v3.20.1
Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash Flows From Operating Activities:      
Net loss $ (17,855) $ (21,516) $ (16,851)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:      
Depreciation and amortization 982 945 1,203
Loss on disposal of assets, net   1,228 505
Provision for bad debts, net 1,695 469 40
Provision for inventory excess and obsolescence 413 166 623
Amortization of discount on debt 140 202  
Amortization of debt issuance costs 188 126  
Loss on patent litigation settlement   1,500  
Stock-based compensation 2,742 2,768 2,207
Warrants issued to consultants 48    
Deferred income taxes 7 (27) (694)
Earned interest income, net 2 1 (42)
Changes in operating assets and liabilities:      
Accounts receivable 655 (1,458) (337)
Inventory 840 (127) 419
Prepaid expenses and other current assets 439 (25) (11)
Accounts payable, accrued and other liabilities (3,156) 1,762 (5,077)
Deferred revenue 114 (161) (397)
Net cash and cash equivalents used in operating activities (12,746) (14,147) (18,412)
Cash Flows From Investing Activities:      
Purchases of property, plant, and equipment (207) (558) (747)
Proceeds from disposal of property, plant, and equipment   36  
Net cash and cash equivalents used in investing activities (207) (522) (747)
Cash Flows From Financing Activities:      
Principal payments under capital lease obligation   (46) (146)
Borrowings under lines of credit   3,696  
Payments under lines of credit   (3,696)  
Proceeds from term loan 2,500 12,500  
Payments of debt issuance costs (133) (1,058)  
Proceeds from equity offerings 9,171   21,761
Payments of fees for shelf registration (821) (164)  
Proceeds from exercise of stock options 4 3 3
Net cash and cash equivalents provided by financing activities 10,721 11,235 21,618
Effect of exchange rate changes (23) (106) 262
(Decrease) increase in cash and cash equivalents (2,255) (3,540) 2,721
Cash, cash equivalents and restricted cash, beginning of year 8,356 11,896 9,175
Cash, cash equivalents and restricted cash, end of year 6,101 8,356 11,896
Supplemental cash flow disclosure - cash paid      
Interest paid 1,784 23 1
Interest received     74
Income taxes paid 35 44 164
Cash paid for operating leases 797    
Supplemental cash flow disclosure - Non-cash investing and financing activities      
Accrued capital expenditures 18 31 $ 102
Loss on patent litigation settlement   1,500  
Settlement of liability awards with RSUs 201    
Right of Use Assets obtained in exchange for a lease liability 276    
Equity financing costs in accounts payable 129    
Warrants issued in connection with debt instruments $ 161 $ 847